The US Food and Drug Administration (FDA) has approved for Abbott’s updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App.
For the first time, care teams can allow US CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones, giving them greater insight into their condition and helping them take a more active role in their care.
Heart failure can worsen long before symptoms become noticeable. Pulmonary artery pressure – the pressure of blood flowing from the heart to the lungs – can rise as heart failure worsens, often weeks before patients experience any symptoms. The CardioMEMS HF System, which has been shown to reduce heart failure hospitalisations and mortality risk, measures pulmonary artery pressure through an implanted sensor in the pulmonary artery.
For more than a decade, clinicians have used pulmonary artery pressure readings from the CardioMEMS HF System to help identify signs of worsening heart failure and guide treatment.
Building on that clinical experience with CardioMEMS, Abbott is continuing to evolve heart failure management with digital tools that help keep clinicians and patients connected between office visits.
The CardioMEMS HF System with the CardioGuide HF App represents an important step toward helping patients take an earlier, more active role in understanding and managing their heart failure.
The new CardioMEMS HF System capabilities also include Dynamic Treatment Plan (DTP), a software feature that allows clinicians to set up personalised medication adjustment plans based on changes in a patient’s pulmonary artery pressure.
Once in place, DTP can send medication adjustment instructions directly to CardioMEMS patients through the CardioGuide HF App, ensuring patients receive timely feedback and guidance from their care team.
